September 2026 Research Update

This month, the clearest pattern came from reports in BRAF V600E-mutant Erdheim-Chester disease: targeted treatments were repeatedly linked with improvement on scans and, in some patients, improvement in day-to-day symptoms. The reports also showed two practical issues patients sometimes run into: treatment side effects that require adjustments, and testing differences where one lab method may not clearly show the BRAF change even when it is present. [1]

In a 3-person series using dabrafenib plus trametinib (a combined BRAF and MEK blocker approach), two people had clinical and radiologic improvement, including resolution of central nervous system (CNS) symptoms. A third person had stable disease, and PET imaging showed decreased disease activity, which was described as an early metabolic improvement. [1]

Safety signals were also visible in these small experiences. One person on dabrafenib plus trametinib developed grade 3 rhabdomyolysis (muscle breakdown), and the report said this led to reducing the dose. [1]

Two single-patient reports also described improvement after BRAF-targeted treatment. One person with unusual breast involvement had a partial metabolic and structural response on FDG-PET after 5 months of vemurafenib. [2]

In a child with CNS involvement and a confirmed BRAF V600E mutation, deterioration was reported after the patient stopped dabrafenib on their own, after earlier postoperative improvement and treatment. This case raised the possibility that ongoing targeted therapy mattered for disease control in that individual, although a single case cannot show what would happen for most patients. [3]

Testing details mattered in one report: in the 3-person series, BRAF V600E staining by immunohistochemistry was faint, equivocal, or negative even though molecular testing confirmed the mutation. For patients, this is a reminder that different test methods can sometimes give different clarity, especially in rare diseases. [1]

For patients and caregivers, these reports add to the real-world picture that BRAF-targeted medicines (such as vemurafenib or dabrafenib, sometimes combined with trametinib) can coincide with improvements in symptoms and imaging when the BRAF V600E change is present. The evidence here is early and based on small numbers, so it does not show how often benefits happen or how long they last, but it makes the month feel more consistent in pointing toward activity of these drugs in BRAF-mutant ECD. It also underscores two uncertainties that can affect patients now: side effects may require changes in treatment, and one type of lab test may not clearly show BRAF V600E even when another test confirms it. [1]

This month also included case reports that expand the range of how Erdheim-Chester disease can show up and how it may be treated in special situations. Together, they emphasize that ECD can involve the brain or heart in ways that look like other conditions at first, and that treatment responses can differ depending on the person and the body areas involved. [4] [5] [3]

One report described isolated CNS Erdheim-Chester disease in a 24-year-old woman who did not respond to corticosteroids, radiotherapy, or cladribine alone but improved after cladribine was combined with cytarabine (Ara-C). After three courses, brain imaging showed remission, and the patient was reported to remain relapse-free for 15 months, with serious but manageable blood-related toxicity including febrile neutropenia. [4]

Two additional reports focused on how ECD can first be recognized through unusual organ findings. One patient in their early 70s presented with chest pain, shortness of breath, and weight loss, and echocardiography showed atrial pseudomasses that were part of the diagnosis. [5]

In the pediatric case, an 11-year-old boy had a mass in the brain ventricular system and bone involvement, with imaging signs described as new for this setting (including a 'crab sign'). The report described surgery and later treatment including dabrafenib, with worsening noted after dabrafenib was stopped. [3]

For patients, these single-patient stories mainly add awareness of the range of ECD rather than changing what is known with certainty. They show that ECD can be limited to the CNS, can appear with heart findings like atrial pseudomasses, and can present in children with brain and bone involvement, which may affect the path to diagnosis and the kinds of tests that get used. The treatment signals (such as cladribine plus cytarabine working after other options failed in one CNS-only case) are important but remain uncertain because they come from one person at a time, so they are best understood as examples of what has been tried when standard paths were not working. [4] [5] [3]